Form 4 for XTNT Xtant Medical Holdings, Inc.
Accepted 2023-08-17 00:00:00 ET · period of report 2023-08-15 · accession 0001235802-23-000092 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-17 | 2023-08-15 | XTNT | McNamara Robert | Dir | A - Grant | $0.00 | +145.2K | 592.0K | +32% | $0 |
| D | 2023-08-17 | 2023-08-15 | XTNT | McNamara Robert | Dir | A - Grant | $0.00 | +28.2K | 28.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-15 | A | A | 145,180 | $0.00 | 591,989 | D | — | — | (F1) These shares are subject to a deferred stock unit award granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, and vest on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. (F2) Includes 145,180 shares issuable upon settlement of deferred stock units granted under the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2023-08-15 | A | A | 28,230 | $0.00 | 28,230 | D | $1.20 · — to 2033-08-15 | 28,230 Common Stock | (F3) This option vests on August 15, 2024, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. |